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Schwann cells (SCs) are the myelin producing cells of the peripheral nervous
system. During development, SCs cease proliferation and differentiate into either
a myelin-forming or non-myelin forming mature phenotype. We are interested
in the role of insulin-like growth factor-I (IGF-I) in SC development. We have
shown previously SCs proliferate in response to IGF-I in vitro. In the current
study, we investigated the role of IGF-I in SC differentiation. SC differentiation
was determined by morphological criteria and expression of myelin proteins.
Addition of 1 mM 8-bromo cyclic AMP (cAMP) or growth on Matrigel matrix
decreased proliferation and induced differentiation of SCs. IGF-I enhanced both
cAMP and Matrigel matrix-induced SC differentiation, as assessed by both mor-
phological criteria and myelin gene expression. Cultured SCs also express IGF
binding protein-5 (IGFBP-5), which can modulate the actions of IGF-I. We exam-
ined the expression of IGFBP-5 during SC differentiation. Both cAMP and Matrigel
matrix treatment enhanced IGFBP-5 protein expression and cAMP increased
IGFBP-5 gene expression five fold. These findings suggest IGF-I potentiates SC
differentiation. The concomitant up-regulation of IGFBP-5 may play a role in
targeting IGF-I to SCs and thus increase local IGF-I bioavailability. J. Cell.
Physiol. 171:161–167, 1997. q 1997 Wiley-Liss, Inc.
Insulin-like growth factor I (IGF-I) can serve as a the myelin-forming cells in the peripheral nervous sys-
tem. Differentiating, myelin-forming SCs express my-differentiating factor for a variety of cell types includ-
elin specific proteins, including protein 0 (P0), myelining osteoblasts, myoblasts and neuroblasts (Pahlman
basic protein (MBP), myelin-associated glycoproteinet al., 1991; James et al., 1993; Ewton and Florini,
(MAG), and P2 (Trapp and Quarles, 1984; Trapp et al.,1995; Thrailkill et al., 1995). The biological effects of
1984) and form a relationship with axons. In vivo, axo-IGF-I are mediated via the type I IGF receptor (IGF-
nal contact is required for the induction of SC differen-IR) (Jones and Clemmons, 1995; Schmid, 1995) and
tiation (Knight et al., 1993), yet, the cellular signalsmodulated by six IGF binding proteins (IGFBP-1 to
underlying axonal regulation of SC differentiation andIGFBP-6) (Holly and Martin, 1994; Jones and Clem-
myelination are not understood. In vitro, agents whichmons, 1995). Expression of IGF-I, IGF-IR and IGFBP
elevate intracellular cAMP level, such as forskolin andis tissue and cell-specific and regulated during develop-
cAMP analogues, mimic axonal effects in cultured SCsment (Bondy et al., 1992; Cerro et al., 1993; Green et
to alter SC morphology and activate the expression ofal., 1994). IGFBPs transport IGF-I to target tissues
myelin proteins including P0 and MBP (Jessen andand modulate IGF-I interactions with IGF-IR in either
Mirsky, 1991; Morgan et al., 1991). Similarly, SC differ-a stimulatory or inhibitory manner (Holly and Martin,
entiation requires the presence of a SC basement mem-1994; Jones and Clemmons, 1995).
brane (Bunge et al., 1989) and, in vitro, SCs undergoIGFBP-5 is the most conserved IGFBP with 97% iden-
phenotypic differentiation when grown on substrata oftity between human and rodent homologues (Kou et al.,
basement membrane components such as Matrigel ma-1994). IGFBP-5 can associate with cell surface proteins
trix (Yoshino et al., 1990).(Andress, 1995; Jones and Clemmons, 1995) and bind to
We recently reported that IGFBP-5 is expressed incomponents of the extracellular matrix (Jones et al.,
1993; Clemmons et al., 1994). While IGFBP-5 may have
IGF independent effects (Andress and Birnbaum, 1992; Contract Grant sponsor: National Institutes of Health; Contract
Grant number R29 NS32843; Contract Grant sponsor: JuvenileJones et al., 1993; Jones and Clemmons, 1995), it also
Diabetes Foundation; Contract Grant number 194130.can potentiate IGF-I action. For example, in fibroblasts,
IGFBP-5 binds to the extracellular matrix and augments *Correspondence to: Eva L. Feldman, M.D., Ph.D. University of
Michigan, Department of Neurology, 4414 Kresge III, Box 0588,IGF-I action (Jones et al., 1993).
Ann Arbor, MI 48109.We are interested in the role of IGF-I in peripheral
nervous system myelination. Schwann cells (SCs) are Received 8 August 1996; Accepted 28 November 1996
q 1997 WILEY-LISS, INC.
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developing rat SCs (Cheng et al., 1996b). Additionally, genes and undergoing myelination when cocultured
with sensory neurons (Tennekoon et al., 1987; Pedenafter peripheral nerve injury in adult rodents, we found
that invading macrophages produce IGF-I and acti- et al., 1990). In the presence of forskolin, MT4H1 SCs
express a similar phenotype to primary SCs. We pre-vated SCs express both IGF-IR and IGFBP-5 (Cheng
et al., 1996a). In vitro, we discovered that undifferenti- viously reported IGF-I is a mitogen for MT4H1 SCs
and demonstrated these cells express both the type Iated SCs express IGF-IR and IGFBP-5 (Cheng et al.,
1996a) and that IGF-I protects SC secreted IGFBP-5 IGF receptor and IGFBP-5 (Cheng et al., 1996a).
MT4H1 cells were maintained in DMEM containingfrom proteolysis (Cheng et al., 1996a). These data have
led us to speculate that during development or after 10% FBS, 100 mM ZnSO4, and 100 mg/ml G418 at 377C
in a humidified atmosphere with 10% CO2. Wheninjury, Schwann cells secrete IGFBP-5, which may in-
crease local IGF-I bioavailability (Cheng et al., 1996a). reaching 80% confluency, cells were subcultured with
trypsin-ethylenediamine tetraacetic acid (EDTA) intoWe believe IGF-I, in turn, may enhance Schwann cell
differentiation and myelination. In the current study, T75 flasks. In some experiments, cells were grown in
defined glial cell medium, designated G3, containingwe address these ideas and propose a role for IGF-I
and IGFBP-5 in Schwann cell differentiation. 50 mg/ml transferrin, 10 ng/ml biotin, and 30 nM sele-
nium in DMEM (Cheng et al., 1996a).
MATERIALS AND METHODS
Morphological studies of SC differentiationDulbecco’s modified Eagle medium (DMEM) was pur-
chased from Gibco BRL (Gaithersburg, MD) and fetal Cells were washed twice and plated into Lab-Tek
chamber slides (Nunc, Naperville, IL) with DMEM con-bovine serum (FBS) from Hyclone (Logan, UT). Other
tissue culture supplies were obtained from Corning taining 0.3% FBS at a density of 3 1 104 cells/cm2 in
the presence of increasing concentrations of (0, 1, 3, 10Glass Works (Corning, NY) and Costar (Cambridge,
MA). Restriction enzymes were from Gibco BRL and nM) IGF-I in the presence or absence of 1 mM 8-bromo
cAMP. In some studies, cells were plated on GrowthNew England Biolabs (Beverly, MA). 32P-dCTP was ob-
tained from Amersham (Arlington Heights, IL). Recom- Factor Reduced-Matrigel matrix from Collaborative
(Bedford, MA). After 24 hr, the morphology of cells wasbinant human IGF-I was a generous gift of Cephalon
(West Chester, PA) and was stored in 100 mM acetic examined under a phase-contrast microscope.
acid in 0807C until use. All other chemicals were pur-
Northern analysischased from Sigma Chemical Co. (St. Louis, MO).
SC were plated (3 1 106 cells/T75 flask) in DMEM
Antibodies and 10% FBS. After 2 days, the medium was removed,
cells were rinsed twice in DMEM, and placed in G3The anti-IGFBP-5 antibody (Upstate Biotechnology,
Lake Placid, NY) used in this study is a polyclonal antisera media with 10 nM IGF-I in the presence or absence of
1 mM 8-bromo cAMP. After 24 hr, the culture mediaraised against immunoaffinity purified IGFBP-5 from the
conditioned media of transfected CHO cells. This anti- was collected and the cells harvested for RNA using
the guanidine isothiocyanate method (Chomczynskisera recognizes IGFBP-5 from human and rat. The
cross-reactivities with other binding proteins are as fol- and Sacchi, 1987). Total RNA (10 mg) was separated by
size in formaldehyde-agarose gels and transferred tolows: IGFBP-1, õ0.5%; IGFBP-2, õ0.1%; IGFBP-3,
õ0.1%; and IGFBP-4, less than 0.5%. The monoclonal nylon nytran membranes (Schleicher and Schuell,
Keene, NH). Membranes were hybridized with 32P-anti-MBP antiserum (Boehringer Mannheim, India-
napolis, IN) recognizes residues 130–137 of MBP from dCTP labeled (0.1–10 1 108 cpm/mg) cDNA probes for
rat IGFBP-5 and glyceraldehyde-3-phosphate dehydro-human, chimpanzee, monkey, rabbit, bovine, and rat.
The anti-P0 antiserum (P07) is a gift from Dr. Michael genase (GAPDH). Individual nytran membranes were
hybridized by stripping and reprobing, as describedShy, Wayne State University, Detroit, MI and was orig-
inally developed by Dr. J. J. Archelos, Julius-Maximil- in the manufacturer’s instructions (Schleicher and
Schuell, Keene, NH). Relative optical density for eachians-Universität Wurzbürg, Wurzbürg, Germany.
hybridization was determined densitometrically by av-
cDNA probes eraging several exposures in the linear range of the
film. These values were expressed as a percentage ofThe rat IGFBP-5 cDNA was received from Dr. Shuni-
chi Shimasaki, The Whittier Institute, La Jolla, CA. A the G3 control and were divided by the percentage of
control values similarly obtained from GAPDH hybrid-300-bp rat IGFBP-5 cDNA, which encodes portions of
the mature peptide, in pBluescript SK/ plasmid was ization (Cheng et al., 1996a).
generated by SacII and HindIII digestion. The cDNA
Immunoblottingprobes were purified with a Magic PCR Prep DNA Puri-
fication Kit from Promega (Madison, WI). Protein (50 mg) of concentrated conditioned media
(for IGFBP-5 immunoblots) or whole cell lysates (for
Cell culture P0 immunoblots) were mixed at a 5:1 ratio with 101
SDS-sample buffer [100 mM Tris (pH 8), 10 mM EDTA,MT4H1 rat SC (SC) were provided kindly by Dr. Gi-
han Tennekoon, Children’s Hospital of Philadelphia, 10% SDS, 100 mM dithiothreitol, 0.1% bromphenol
blue, and 20% glycerol] and boiled for 3–5 min. Sam-Philadelphia, PA. These cells have been transfected
with simian virus 40 (SV 40) large T antigen under the ples were separated by SDS-PAGE (12.5%) and electro-
phoretically transferred to nitrocellulose. Nitrocellu-control of the metallothionine promoter (Tennekoon et
al., 1987). Expression of SV 40 large T antigen is sup- lose membranes were blocked with 5% nonfat dried
milk in TBST [20 mM Tris, 0.16 M NaCl, and 0.10%pressed in the absence of zinc. Under these conditions,
the cells behave like primary SCs expressing myelin Tween-20 (pH 7.4)]. The membranes were then incu-
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Fig. 1. The effects of 8-bromo cAMP and IGF-I on SC morphology. Fig. 2. The effects of Matrigel matrix and IGF-I on SC morphology.
A: When plated on Matrigel-coated plates, SCs became polygonal andA: SCs extended processes and became smaller polygonal cells after
24 hr of treatment with 1 mM 8-bromo cAMP (arrow). B: Differentiat- extended processes (arrow). B: In the presence of 1 nM IGF-I, SCs
cultured on Matrigel-coated plates became slender with long pro-ing SCs clumped together after treatment with 1 nM IGF-I / 1 mM
8-bromo cAMP (arrow). C: IGF-I (3 nM) with 1 mM 8-bromo cAMP cesses. The cells tended to adhere to each other (arrow). C: IGF-I (3
nM) further promoted Matrigel-coupled SC aggregation and processfurther promoted SC clumping and process extension (arrow). D: SCs
became very slender bipolar cells that bundled together to form fasci- elongation (arrow). D: SCs on Matrigel formed fascicles (arrow) with
10 nM IGF-I. Data are from one of three representative experiments.cles (arrow) in the presence of 10 nM IGF-I / 1 mM 8-bromo cAMP.
Data are from one of three representative experiments. A and D, bar Bar Å 50 mM.
Å 25 mM. B and C, bar Å 50 mM.
IGF-I enhanced the morphological changes. IGF-I (3
nM) treatment induced more cell aggregation (Fig. 1C),bated for 2 hr with IGFBP-5 antiserum (1:1000) or anti-
P0 (1:1000), in TBST / 5% milk, washed extensively whereas in the presence of 10 nM IGF-I, SCs assumed a
slender bipolar configuration (tubular aggregates) withduring a 30-min period with TBST, and then incubated
for 1 hr with horseradish peroxidase-conjugated goat long processes. Cells also formed colonies with fascicles
consisting of bundles of long cell processes radiatinganti-rabbit antibody (1:7500, Santa Cruz Biotechnol-
ogy) for IGFBP-5 or horse anti-mouse (1:1000, Santa out of each colony connecting to neighboring colonies
(Fig. 1D).Cruz Biotechnology) for P0 in TBST / 5% milk. After
40 min of extensive washing, nitrocellulose membranes We also used the artificial basement membrane ma-
trix, Matrigel matrix, to induce SC differentiation. SCswere incubated with enhanced chemiluminescence re-
agents (Amersham). Bound protein-antibody com- plated on Matrigel changed from a round, flattened
morphology to a more bipolar or triangular configura-plexes were visualized by autoluminography on reflec-
tion-NEF film (Du Pont, Boston, MA). tion (Fig. 2A). SCs became elongated after the addition
of 1 nM IGF-I (Fig. 2B) whereas 3 nM IGF-I treatment
RESULTS promoted the formation of cell fascicles and the exten-
8-bromo cAMP and matrigel matrix induce SC sion of processes (Fig. 2C). In the presence of 10 nM
differentiation IGF-I, SCs formed similar structures to the cells
treated with IGF-I and 8-bromo cAMP (Fig. 2D). Thus,SCs express different phenotypes while undergoing
differentiation (Yoshino et al., 1990; De Deyne et al., IGF-I affected SC morphology in at least two ways: by
promoting cell clustering and by facilitating the exten-1994). We and others have observed that undifferenti-
ated MT4H1 SCs have a flattened, round morphology sion of processes. Essentially, all SCs underwent the
morphological changes depicted in Figs. 1 and 2.when cultured on plastic tissue culture dishes (Yoshino
et al., 1990; De Deyne et al., 1994). Upon differentia- Differentiation not only induces changes in SC mor-
phology but also activates the expression of myelin pro-tion, SCs assume a distinct morphology, form polygonal
and/or tubular aggregates and extend cellular pro- teins including P0 and myelin basic protein (MBP). To
quantitate enhanced SC differentiation, we examinedcesses (Yoshino et al., 1990; De Deyne et al., 1994). We
initially induced SC differentiation using two known P0 protein expression. After incubation in the presence
or absence of 8-bromo cAMP and/or 10 nM IGF-I, SCSC differentiating factors: the cAMP analogue, 8-bromo
cAMP and Matrigel matrix (Knight et al., 1993). After whole cell lysates were collected and the extracted pro-
teins were separated by SDS-PAGE followed by P0 im-treatment with 1 mM 8-bromo cAMP for 24 hr, SCs
became smaller, polygonal cells and extended processes munoblotting procedures. P0 immunoblots demon-
strated the presence of the 30 kD P0 protein (Fig. 3).(Fig. 1A). To test the effect of IGF-I on cAMP induced
morphological changes, SCs were treated with increas- IGF-I (10 nM) enhanced P0 expression in comparison
with untreated cells or cells treated with 1 mM 8-bromoing concentrations of IGF-I in the presence of 1 mM 8-
bromo cAMP. With the addition of 1 nM IGF-I, SCs cAMP alone (Fig. 3). Maximal P0 protein expression
was detected in cells treated for 2 days with both 8-began to group together and form aggregates, with long
cellular processes (Fig. 1B). Higher concentrations of bromo cAMP and 10 nM IGF-I (Fig. 3). In parallel,
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Similar results were observed with cAMP treatment.
SCs were incubated in defined media in the presence
or absence of 1 mM 8-bromo cAMP and/or 10 nM IGF-
I. Conditioned media were collected and concentrated,
and proteins were separated by SDS-PAGE followed by
IGFBP-5 immunoblotting. As in our previous experi-
ments, we again observed that secreted IGFBP-5 was
degraded in the absence but protected in the presence
of IGF-I. 8-bromo cAMP (1 mM) significantly enhanced
the expression of IGFBP-5 in the presence of 10 nM
IGF-I (Fig. 5A). We then examined the effects of two
Fig. 3. IGF-I enhances P0 expression. P0 immunoblots were pre- additional agents that elevate intracellular cAMP, for-pared from whole-cell lysates of SCs cultured in 1 mM 8-bromo cAMP { skolin and dibutyryl cAMP, on IGFBP-5 expression.10 nM IGF-I. IGF-I (10 nM) alone promoted P0 expression (lanes 4
These agents had the same effects as 8-bromo cAMPand 8) with maximal enhancement by day 2 (lane 8). 8-bromo cAMP
enhanced P0 protein expression only in the presence of 10 nM IGF-I and enhanced IGFBP-5 expression in SC conditioned
(compare lanes 2 and 6 with lanes 3 and 7, respectively). Data are media in the presence of IGF-I (Fig. 5B).from one of three representative experiments. We then asked if the effects of cAMP on IGFBP-5
protein expression was secondary to enhanced IGFBP-
5 gene expression. Northern analysis was performed
using RNA isolated from SCs cultured under the same
conditions as the immunoblot experiments. As we have
previously reported, IGF-I had no effect on IGFBP-5
gene expression (Cheng et al., 1996a). However, addi-
tion of cAMP increased IGFBP-5 gene expression five-
fold (Fig. 6).
DISCUSSION
The IGF family of ligands, receptors and binding pro-
teins are essential for normal nervous system develop-
ment (Carson et al., 1993; Liu et al., 1993) and instru-
mental in nervous system regeneration (Hansson,Fig. 4. Matrigel matrix promotes SC IGFBP-5 expression. IGFBP-5
1993). We are interested in how IGF family membersimmunoblots were prepared using concentrated conditioned media
from SCs grown in G3 media on Matrigel-coated or plastic plates { affect the development and repair of the peripheral ner-
10 nM IGF-I. There was no 30-kD IGFBP-5 signal detected under vous system (Sullivan and Feldman, 1994; Cheng et
either plating conditions in the absence of IGF-I. In the presence of al., 1996a,b). Although these are separate processes,10 nM IGF-I, the level of IGFBP-5 in the media of SCs cultured on
each is dependent on successful myelination of axonsMatrigel-coated plates was higher than that from SCs grown on plas-
tic uncoated plates. Data from one of three representative experi- by differentiated SCs (Trapp et al., 1981, 1984; Trapp
ments. and Quarles, 1984; Owens and Bunge, 1990; Jessen
and Mirsky, 1991). In the current study, we examined
the role of IGF-I and IGFBP-5 in SC differentiation, as
a first step in understanding the role of IGF familywe observed low amounts of MBP immunoreactivity in
untreated SCs. Treatment with 1 mM 8-bromo cAMP members in peripheral nervous system biology.
We have shown previously that IGF-I is a mitogenmodestly enhanced the expression of MBP immunore-
active protein while the most intense immunofluores- for newly cultured SCs (Cheng et al., 1996a). However,
once SCs have begun to mature, we found that IGF-Icence was observed in cells treated with both cAMP
and IGF-I (data not shown). assumed a new role, that of a differentiating factor.
After treatment with cAMP, IGF-I enhanced SC differ-
IGFBP-5 expression is increased with SC entiation. Markers of SC differentiation included mor-
differentiation phological changes and enhanced P0 and MBP expres-
sion. In parallel, De Deyne and colleagues have re-SCs express IGFBP-5 (Cheng et al., 1996a); interest-
ingly, IGFBP-5 is enhanced during differentiation in ported (1994) that SCs respond to cAMP by assuming
a differentiated morphology characterized by reorgani-multiple cell types and may play a role in the mainte-
nance of a differentiated phenotype (Birnbaum and zation of microtubules. In our studies, IGF-I not only
enhanced this process but also promoted cell clusteringWiren, 1994; Ewton and Florini, 1995; Rotwein et al.,
1995). In the current study, we examined the levels of and enhanced P0 and MBP expression. Interestingly,
cell clustering is important for P0 expression (KnightIGFBP-5 produced by SCs upon differentiation. Condi-
tioned media of SCs cultured on Matrigel-coated plates et al., 1993). Consequently, we do not know whether
the increase in P0 expression was due to a direct effectwere collected and concentrated, and equal amounts
of protein were separated by SDS-PAGE followed by of IGF-I signaling or secondary to the IGF-I coupled
morphological changes.IGFBP-5 immunoblotting. As we have previously ob-
served (Cheng et al., 1996a), secreted IGFBP-5 was Similar phenomena were observed when SCs were
grown on Matrigel. Matrigel contains many of the com-degraded in the absence but protected in the presence
of IGF-I. Matrigel coating significantly enhanced the ponents of the SC basement membrane including lami-
nin, type I and type IV collagen (McGarvey et al., 1984).expression of IGFBP-5 in the presence of 10 nM IGF-
I (Fig. 4). Laminin, the major component of Matrigel, promotes
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for IGF-I stimulation of cellular migration. Collectively,
our results with SCs and neurons (Leventhal and Feld-
man, 1996; Leventhal et al., 1996) as well as the recent
data of Doerr and Jones with breast cancer cells (Doerr
and Jones, 1996) imply important cross-talk between
IGF-I and integrin signaling cascades. We speculate
that this link may be instrumental in IGF-I enhance-
ment of SC differentiation.
We recently reported that cultured SCs primarily ex-
press IGFBP-5 (Cheng et al., 1996a). In the current
study, we observed that treatment with either Matrigel
or cAMP increased IGFBP-5 expression while mediat-
ing SC differentiation. Several other examples of
IGFBP-5 enhancement with cellular differentiation im-
ply this process may be an important component of
normal tissue maturation. For example, enhanced ex-
pression of IGFBP-5 occurs during terminal muscle dif-
ferentiation (James et al., 1993; Ewton and Florini,
1995; Rotwein et al., 1995; Duan et al., 1996). Although
IGFBP-5 is not detectable in dividing myoblasts (Ewton
and Florini, 1995), there is a marked increase in both
IGFBP-5 mRNA and protein during myoblast differen-
tiation (James et al., 1993; Ewton and Florini, 1995),
coincident with onset of myogenin gene expression
(Rotwein et al., 1995). Rotwein and colleagues recently
found that the rapid upregulation of IGFBP-5 during
muscle differentiation is mediated, in part, by a 156Fig. 5. cAMP analogues promote SC IGFBP-5 expression. IGFBP-5
nucleotide region of the IGFBP-5 promoter containingimmunoblots were prepared using concentrated conditioned media
from SCs grown on plastic plates { 10 nM IGF-I for 1 or 2 days. several potential binding sites for muscle cell-related
A: In the absence of IGF-I, IGFBP-5 was degraded in SC conditioned transcription factors (Rotwein et al., 1995).
media (lanes 1, 2, 5, and 6). A 23-kD proteolytic fragment was visual- We also found that secreted IGFBP-5 was degradedized after 2 days. In the presence of IGF-I, 1 mM 8-bromo cAMP
in the absence but protected in the presence of IGF-I.enhanced the levels of IGFBP-5 in SC conditioned media (compare
lanes 3 and 7 with lanes 4 and 8). B: In the presence of 10 nM IGF- These results parallel our previous reports that IGF-I
I, 50 mM forskolin (lane 3), 1 mM 8-bromo cAMP (lane 4), and 1 mM protects SC secreted IGFBP-5 from proteolysis (Cheng
dibutyryl cAMP (lane 5) each increased IGFBP-5 expression in SC et al., 1996a). In both our past (Cheng et al., 1996a)conditioned media in comparison with G3 control (lane 1) and 10 nM
and current studies, proteolysis of IGFBP-5 resulted inIGF-I alone (lane 2). Data from one of three representative experi-
ments. a 23-kD degraded fragment. Several IGFBP-5 prote-
ases have been isolated and characterized (Conover et
al., 1993; Clemmons et al., 1994; Nam et al., 1994;
Thrailkill et al., 1995). A set of 52- to 72-kD IGFBP-5the adhesion and differentiation of cultured SCs and
Schwannoma cells by interacting with integrin recep- proteases isolated from osteoblast conditioned media are
cation-dependent matrix metalloproteinases (Thrailkilltors (McGarvey et al., 1984; Baur et al., 1995). In the
current study, IGF-I enhanced Matrigel-coupled mor- et al., 1995). Interestingly, these IGFBP-5 proteases
are upregulated during osteoblast differentiationphological differentiation in SCs. Similar enhancement
has been reported when SCs are cultured on Matrigel (Thrailkill et al., 1995), suggesting IGFBP-5 proteases
also are involved in IGF-I regulation of cellular differ-in 5% fetal bovine serum (Yoshino et al., 1990). Our
results suggest that IGF-I is one of the serum factors entiation.
The marked increase in IGFBP-5 expression duringthat contributes to these previous reports of serum en-
hancement of Matrigel-mediated SC differentiation. SC differentiation led us to examine the effects of cAMP
analogues on IGFBP-5 gene expression. As has beenLike our observations with cAMP, we do not yet know
the underlying mechanism of IGF-I enhancement of observed previously in human fibroblasts (Duan and
Clemmons, 1995), we found that treatment with cAMPMatrigel coupled SC differentiation. However, both our
own work in neurons (Leventhal and Feldman, 1996; analogues increased IGFBP-5 gene expression. Re-
cently, an AP-2 binding site was identified on theLeventhal et al., 1996) and a recent report in breast
cancer cells (Doerr and Jones, 1996) suggest an interac- IGFBP-5 promoter, suggesting a direct interaction be-
tween the cAMP-response element and the IGFBP-5tion between IGF-I receptor downstream signaling cas-
cades and integrin-mediated intracellular signaling promoter (Duan and Clemmons, 1995). Our results cor-
roborate this concept and imply that previous reportspathways, known to induce SC differentiation. We have
reported recently that IGF-I, as well as integrin bind- of increased IGFBP-5 gene expression by hormones
(Camacho-Hubner et al., 1992) may actually be medi-ing, stimulates the activation of two proteins involved
in neuronal adhesion, focal adhesion kinase and paxil- ated via cAMP. Similarly, our results of enhanced
IGFBP-5 gene expression during SC differentiationlin (Leventhal and Feldman, 1996; Leventhal et al.,
1996). In parallel, Doerr and Jones (1996) have re- also parallel the upregulation of IGFBP-5 observed
during myoblast (James et al., 1993; Ewton and Florini,ported that interaction of vitronectin with the avb5
integrin or collagen with the a2b1 integrin is required 1995; Rotwein et al., 1995; Duan et al., 1996) and osteo-
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is augmented by the ability of SCs to secrete IGFBP-
5, which, in turn, may bind SC basement membrane
and increase local IGF-I bioavailability. IGF-I then
serves to maintain the differentiated SC phenotype.
In support of this concept, we have demonstrated an
upregulation of SC IGFBP-5 gene and protein expres-
sion during SC differentiation as well as the ability of
IGF-I to enhance this process. Further investigation
into the function of IGF-I/IGFBP-5 in the peripheral
nervous system may provide additional insights into
the role of the IGF family in nervous system develop-
ment and differentiation.
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